At this time, MiHA-based immunotherapy in the setting of HSCT is one of the most potent forms of cancer treatment, but it remains non-specific and can lead to widespread anti-host alloreactivity in the form of Graft-versus-host disease (GVHD) [5]. The gene discussed is XIAP; the disease is graft versus host disease.